| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| D D Mille. The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 8. issue 2. 1996-12-26. PMID:8807035. |
the discussion includes guidelines regarding the clinical use of clozapine plasma concentrations in the pharmacological management of persons with treatment-refractory schizophrenia. |
1996-12-26 |
2023-08-12 |
Not clear |
| M A Fuller, G Jurjus, K Kwon, P E Konicki, G E Jaski. Clozapine reduces water-drinking behavior in schizophrenic patients with polydipsia. Journal of clinical psychopharmacology. vol 16. issue 4. 1996-12-20. PMID:8835710. |
we conclude that clozapine may be a highly effective treatment for polydipsia in patients with treatment-refractory schizophrenia. |
1996-12-20 |
2023-08-12 |
Not clear |
| R Ranjan, H Y Meltze. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biological psychiatry. vol 40. issue 4. 1996-12-18. PMID:8871771. |
three cases of resistant psychotic depression were treated with clozapine monotherapy, an atypical antipsychotic drug effective in treatment-resistant schizophrenia and mania. |
1996-12-18 |
2023-08-12 |
Not clear |
| H Y Meltzer, P A Thompson, M A Lee, R Ranja. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 14. issue 3 Suppl. 1996-12-13. PMID:8866741. |
cognitive measures predict work function and overall outcome on clozapine as assessed by the global assessment scale and quality-of-life scale in neuroleptic--resistant schizophrenia. |
1996-12-13 |
2023-08-12 |
Not clear |
| J Gerlach, H Lublin, L Peacoc. Extrapyramidal symptoms during long-term treatment with antipsychotics: special focus on clozapine and D1 and D2 dopamine antagonists. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 14. issue 3 Suppl. 1996-12-13. PMID:8866742. |
other receptor affinities may contribute to the beneficial effect of clozapine in eps and schizophrenia. |
1996-12-13 |
2023-08-12 |
Not clear |
| R Gray, N Smedley, K Miller, S Vearnal. Health education needs of people with schizophrenia taking clozapine. Journal of clinical nursing. vol 5. issue 5. 1996-12-13. PMID:8932035. |
health education needs of people with schizophrenia taking clozapine. |
1996-12-13 |
2023-08-12 |
Not clear |
| M Poyurovsky, H Hermesh, A Weizma. Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients. Clinical neuropharmacology. vol 19. issue 4. 1996-12-06. PMID:8828993. |
interest in the association of obsessive-compulsive (oc) symptoms and schizophrenia has been reawakened since the introduction of clozapine for treatment of schizophrenia. |
1996-12-06 |
2023-08-12 |
Not clear |
| B Gallhofer, U Bauer, S Lis, S Krieger, H Grupp. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 6 Suppl 2. 1996-12-04. PMID:8792116. |
in view of the restrictions on the use of clozapine, it is suggested that risperidone should be more widely used in schizophrenia because it preserves cognitive function better than conventional neuroleptics and is therefore likely to allow patients to have better insight into their illness and to have better long-term quality of life expectations. |
1996-12-04 |
2023-08-12 |
Not clear |
| G Bondolfi, P Baumann, H Dufou. Treatment-resistant schizophrenia: clinical experience with new antipsychotics. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 6 Suppl 2. 1996-12-04. PMID:8792117. |
risperidone, which is effective in chronic schizophrenia and has a low side effect profile and does not require routine blood monitoring, was compared with clozapine in a double-blind comparative study in 86 treatment-resistant patients. |
1996-12-04 |
2023-08-12 |
Not clear |
| K T Matsuda, M C Cho, K M Lin, M W Smith, A S Young, J A Adam. Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacology bulletin. vol 32. issue 2. 1996-12-03. PMID:8783895. |
this study compares dosage, efficacy, and side-effect profiles in 17 korean-american and 17 caucasian age- and sex-matched schizophrenia or schizoaffective patients treated with clozapine. |
1996-12-03 |
2023-08-12 |
Not clear |
| H J Koponen, E Leinonen, U Lepol. Fluvoxamine increases the clozapine serum levels significantly. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 6. issue 1. 1996-12-03. PMID:8866941. |
in this case report we describe an interaction between clozapine and fluvoxamine in two physically healthy patients meeting the dsm-iiir criteria for paranoid schizophrenia. |
1996-12-03 |
2023-08-12 |
Not clear |
| P L Needham, J Atkinson, M J Skill, D J Hea. Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile. Psychopharmacology bulletin. vol 32. issue 1. 1996-11-27. PMID:8927661. |
zotepine, an atypical antipsychotic structurally similar to clozapine, is in phase iii clinical trials in the united states and europe for the treatment and management of acute and chronic schizophrenia. |
1996-11-27 |
2023-08-12 |
human |
| R Benatov, P Sirota, S Megge. Neuroleptic-resistant schizophrenia treated with clozapine and ECT. Convulsive therapy. vol 12. issue 2. 1996-11-25. PMID:8744173. |
neuroleptic-resistant schizophrenia treated with clozapine and ect. |
1996-11-25 |
2023-08-12 |
Not clear |
| R Benatov, P Sirota, S Megge. Neuroleptic-resistant schizophrenia treated with clozapine and ECT. Convulsive therapy. vol 12. issue 2. 1996-11-25. PMID:8744173. |
we present four patients with schizophrenia treated with clozapine and ect. |
1996-11-25 |
2023-08-12 |
Not clear |
| G P Reynold. The importance of dopamine D4 receptors in the action and development of antipsychotic agents. Drugs. vol 51. issue 1. 1996-11-07. PMID:8741229. |
although it has a lower affinity than the d2 receptor for most antipsychotic drugs, the d4 receptor has a higher affinity for clozapine, which may explain the unique efficacy of clozapine in the treatment of schizophrenia. |
1996-11-07 |
2023-08-12 |
Not clear |
| G P Reynold. The importance of dopamine D4 receptors in the action and development of antipsychotic agents. Drugs. vol 51. issue 1. 1996-11-07. PMID:8741229. |
however, there is no association between genetic alterations of the d4 gene and either the development of schizophrenia or response to clozapine administration, nor is the absence of the receptor related to major neuropsychiatric deficits. |
1996-11-07 |
2023-08-12 |
Not clear |
| J A Bennett, P E Kec. A target-dose finding study of clozapine in patients with schizophrenia. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 8. issue 1. 1996-11-07. PMID:8743644. |
a target-dose finding study of clozapine in patients with schizophrenia. |
1996-11-07 |
2023-08-12 |
Not clear |
| J A Bennett, P E Kec. A target-dose finding study of clozapine in patients with schizophrenia. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 8. issue 1. 1996-11-07. PMID:8743644. |
twelve patients with schizophrenia by dsm-iii-r criteria who were refractory to treatment with standard antipsychotics were treated with clozapine utilizing a 10- to 14-day titration to a target dose of 6 mg/kg/day. |
1996-11-07 |
2023-08-12 |
Not clear |
| F Vahid-Ansari, Y Nakabeppu, G S Robertso. Contrasting effects of chronic clozapine, Seroquel(TM) (ICI 204,636) and haloperidol administration of deltaFosB-like immunoreactivity in the rodent forebrain. The European journal of neuroscience. vol 8. issue 5. 1996-11-06. PMID:8743740. |
these results suggest that a preferential action on limbic structures such as the prefrontal cortex, ventral striatum and lateral septal nucleus may account for the ability of chronic clozapine and ici 204, 636 administration to reduce the symptoms of schizophrenia without generating extrapyramidal side effects. |
1996-11-06 |
2023-08-12 |
rat |
| M Zhang, R R Owen, S K Pope, G R Smit. Cost-effectiveness of clozapine monitoring after the first 6 months. Archives of general psychiatry. vol 53. issue 10. 1996-11-06. PMID:8857873. |
clozapine is effective in treating patients with schizophrenia who do not respond to conventional neuroleptic drugs. |
1996-11-06 |
2023-08-12 |
Not clear |